Recaticimab

瑞卡西单抗

Report date: 2025/01/13 15:34:36

Base Information

Drug NameRecaticimab
Drug Alias Name艾心安SHR-1209
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHypercholesterolemiaHyperlipidemiasDyslipidemias +[6] 
Global Approved IndicationsHypercholesterolemiaDyslipidemias
Approved Indications in ChinaHypercholesterolemiaDyslipidemias
Original Approved Country/TerritoryMainland China
Original Approved Date2025/01/08
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJiangsu Hengrui Medicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuangdong Hengrui Pharmaceutical Co LtdSun Yat-Sen Memorial Hospital Of Sun Yat-Sen UniversityShanghai Hengrui Pharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaHyperlipidemiasDyslipidemias +[5] 
Inactive IndicationsHyperlipoproteinemia Type II

Other Information

ATC CodeN/A
Related LinksN/A